Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Bright Minds Biosciences Inc. (NASDAQ: DRUG).The analyst commented, "DRUG’s lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE